Current report no.: 3/2017 Date: 2017-03-13 Information about conclusion of a contract for financial subsidy for Bioton S.A.'s project from the Operational Programme Smart Growth 2014-2020.

Bioton S.A. ("Company") informs that on 13.03.2017, the Company and the National Centre for Research and Development ("NCRD") concluded a contract for financial subsidy for the project "Development of the innovative technology of short-acting and long-acting insulin analogues applicable in the treatment of diabetes" ("Project") under the Operational Programme Smart Growth 2014-2020 - action 1.1 "R&D projects of the companies", sub- action 1.1.1 "Industrial research and development works conducted by entrepreneurs" ("Contract").

Total value of the Project equals to 50.684.467,63 PLN.

The maximum amount of expenditure eligible for support equals to 50.684.467,63 PLN.

On the basis of the Contract, the Company has been granted with a finacial subsidy up to the amount of 20.988.427,57 PLN.

As a performance bond, the Company shall issue and lodge with NCRD a blank promissory note along with a promissory note declaration. Terms and conditions of the Contract do not differ from those commonly applied in agreements of this kind.

Conclusion of the Contract is a result of positive evaluation of the application for financial subsidy for the Project, which the Company informed about on 28.10.2016 by the way of current report no. 48/2016.

In opinion of the Management Board of the Company, conclusion of the Contract enables to develop the Company's portfolio of medicines used for treatment of diabetes, extending it by the insulin analogues.

Bioton SA published this content on 13 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 20 March 2017 08:16:07 UTC.

Original documenthttp://bioton.pl/pdf_inwestor/en/current_report/2017/RB_2017_3_en.pdf

Public permalinkhttp://www.publicnow.com/view/DAF305B1927D7CA292CE3EC3A615509EB1105B92